0
0
After the EU Commission signed another contract with a pharmaceutical company, Health Minister Rudolf Anschober (Greens) today emphasized the good progress in coronavirus vaccine research. “Each contract brings us a big step closer to our declared goal of providing a high-quality, safe and effective Covid 19 vaccine for the citizens of the European Union, and thus also for Austria,” he said.
“The intention is to compile a vaccine portfolio, both at European and national level, that is suitable for broadly spreading the risks regarding delayed or missing market approval of individual vaccines, qualitative efficacy and tolerability as well as the possibility of use in different population and risk groups,” Anschober explained in a mailing. “At my request in the Council of Ministers, the German government has determined the funding for these potential vaccine candidates.”
Vaccine candidate in Phase III
The Commission has approved a pre-purchase agreement with Johnson&Johnson’s Belgian subsidiary Janssen Pharmaceutica NV as part of the joint EU procurement process and based on the EU strategy for CoV vaccines.
In the steering committee under the Austrian Presidency, the 27 member states gave their approval. The vaccine candidate is currently in Phase III clinical development. Talks or contract negotiations with CureVac, BioNTech-Pfizer and Moderna as well as with other companies will continue according to the mailing.
Hector Pascua, Source: ORF.at/agencies. Picture: stockilyapp.com
This post has already been read 761 times!
